The immunogenicity and efficacy of acommercially available Infectious Bovine Rhinotracheitis (IBR) virus vaccine against a Pakistani field IBR strain
DOI:
https://doi.org/10.12834/VetIt.2922.19929.3Keywords:
Bovine alphaherpesvirus1, Efficacy, Virus neutralization, Cattle, Reproductive disorder, Partial ProtectionAbstract
Infectious bovine rhinotracheitis (IBR) is a highly communicable disease of cattle and wild ruminants that is caused by Bovine alphaherpesvirus 1 (BoHV‑1). For IBR control, several developed countries have adopted the immunization and eradication programs focusing on IBR‑positive animals. In Pakistan, livestock producers are importing commercially available vaccine of BoHV‑1, but no studies on the efficacy of these commercial vaccines against local isolates are available. Therefore, the present study was aimed to evaluate the efficacy of a commercially available vaccine of BoHV‑1 against local field isolates of virus. The rabbit model was used and the vaccine was evaluated for immunogenicity and protection after challenge with a highly virulent strain of a field virus. The immune response was measured by virus neutralization titers (VNT). This vaccine induced a humoral response in rabbits but that was not sufficient to completely protect the vaccinated animals against the wild‑type BoHV‑1 strain challenge. While a low virus titer compared to control rabbits was observed in the vaccinated rabbits (p<0.05), there was no sterilizing immunity or freedom from infection. However, complete freedom from disease, for example, the absence of pyrexia was noticed in the vaccinated group. In conclusion, the present study demonstrated that imported vaccine stock provoked only a partial protection against indigenous isolated of BoHV‑1. However, tests performed on rabbits are preliminary, as only those performed on the source species can determine more reliable results.
References
DesCôteaux L, Cécyre D, Elsener J, and Beauchamp G. 2003. Comparison of humoral immune responses in dairy heifers vaccinated with 3 different commercial vaccines against bovine viral diarrhea virus and bovine herpesvirus-1. The Canadian Veterinary Journal 44, 816.
Edwards S, White H, and Nixon P. 1990. A study of the predominant genotypes of bovid herpesvirus 1 found in the UK. Veterinary microbiology 22, 213-223.
Fulton R, d’Offay J, Eberle R, Moeller R, Van Campen H, O’Toole D, Chase C, Miller M, Sprowls R, and Nydam D. 2015. Bovine herpesvirus-1: evaluation of genetic diversity of subtypes derived from field strains of varied clinical syndromes and their relationship to vaccine strains. Vaccine 33, 549-558.
Hierholzer J, and Killington R. 1996. Virus isolation and quantitation. In: Virology methods manual, Elsevier, 25-46.
Kamaraj G, Rana S, and Srinivasan V. 2009. Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis. The new microbiologica 32, 135.
Liu F, Wu X, Zou Y, Li L, and Wang Z. 2015. Peste des petits ruminants virus-like particles induce both complete virus-specific antibodies and virus neutralizing antibodies in mice. Journal of virological methods 213, 45-49.
Machado GF, Bernardi F, Hosomi FY, Peiró JR, Weiblen R, Roehe PM, Alessi AC, Melo GD, Ramos AT, and Maiorka PC. 2013. Bovine herpesvirus-5 infection in a rabbit experimental model: immunohistochemical study of the cellular response in the CNS. Microbial pathogenesis 57, 10-16.
Mahajan V, Banga H, Deka D, Filia G, and Gupta A. 2013. Comparison of diagnostic tests for diagnosis of infectious bovine rhinotracheitis in natural cases of bovine abortion. Journal of comparative pathology 149, 391-401.
Marsden HS, McLean GW, Barnard EC, Francis GJ, MacEachran K, Murphy M, McVey G, Cross A, Abbotts AP, and Stow ND. 1997. The catalytic subunit of the DNA polymerase of herpes simplex virus type 1 interacts specifically with the C terminus of the UL8 component of the viral helicase-primase complex. J Virol 71, 6390-6397.
Parreño V, López MV, Rodriguez D, Vena MM, Izuel M, Filippi J, Romera A, Faverin C, Bellinzoni R, and Fernandez F. 2010. Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus. Vaccine 28, 2539-2549.
Raaperi K, Orro T, and Viltrop A. 2014. Epidemiology and control of bovine herpesvirus 1 infection in Europe. The Veterinary Journal 201, 249-256.
Raza S, Deng M, Shahin F, Yang K, Hu C, Chen Y, Chen H, and Guo A. 2016. A bovine herpesvirus 1 pUL51 deletion mutant shows impaired viral growth in vitro and reduced virulence in rabbits. Oncotarget 7, 12235-12253.
Rehman HU, Rabbani M, Ghafoor A, Riaz A, Awan FN, and Raza S. 2020. First Isolation and Genetic Characterization of Bovine Herpesvirus 1 From Cattle in Pakistan.
Ruiz-Saenz J, Jaime J, Ramirez G, and Vera V. 2012. Molecular and in vitro characterization of field isolates of bovine herpesvirus-1. Virologica Sinica 27, 26-37.
Ruiz-Sáenz J, Jaime J, and Vera V. 2013. An inactivated vaccine from a field strain of bovine herpesvirus-1 (BoHV-1) has high antigenic mass and induces strong efficacy in a rabbit model. Virologica Sinica 28, 36-42.
Sambamurti K, Refolo LM, Shioi J, Pappolla MA, and Robakis NK. 1992. The Alzheimer's amyloid precursor is cleaved intracellularly in the trans-Golgi network or in a post-Golgi compartment. Ann N Y Acad Sci 674, 118-128.
Thiry J, Keuser V, Muylkens B, Meurens F, Gogev S, Vanderplasschen A, and Thiry E. 2006. Ruminant alphaherpesviruses related to bovine herpesvirus 1. Veterinary research 37, 169-190.
Vargas D, Bohórquez A, Parra J, Jaime J, and Góngora A. 2016. Serological evaluation of bovine herpesvirus 1 and 5 in cattle-breeding systems on Colombia’s high plains. Revista MVZ Córdoba 21, 5381-5389.
Walz PH, Givens MD, Rodning SP, Riddell KP, Brodersen BW, Scruggs D, Short T, and Grotelueschen D. 2017. Evaluation of reproductive protection against bovine viral diarrhea virus and bovine herpesvirus-1 afforded by annual revaccination with modified-live viral or combination modified-live/killed viral vaccines after primary vaccination with modified-live viral vaccine. Vaccine 35, 1046-1054.
